Children's Health Defense Ozempic lawsuits, Wegovy vision loss, GLP-1 drugs, multidistrict litigation, Novo Nordisk, Eli Lilly, drug safety, pharmaceutical lawsuits
The U.S. Judicial Panel on Multidistrict Litigation ordered that all lawsuits claiming the drugs caused partial or complete blindness be grouped in a new multidistrict litigation (MDL) in the Eastern District of Pennsylvania. The panel rejected drugmakers’ request to combine the eye injury cases into an existing MDL targeting severe gastrointestinal side effects.
A surge of lawsuits alleging Ozempic, Wegovy and other weight-loss drugs caused sudden vision loss were consolidated into a new federal mass litigation Monday. It’s the second major legal battle confronting manufacturers of the blockbuster drugs, Reuters reported.
The U.S. Judicial Panel on Multidistrict Litigation ordered that all lawsuits claiming the drugs, also used to treat diabetes, caused partial or complete blindness be grouped in a new multidistrict litigation (MDL) in Pennsylvania.
The panel rejected drugmakers’ request to combine the eye injury cases into an existing MDL targeting severe gastrointestinal side effects, agreeing with plaintiffs that the vision loss claims involve different medical issues and require separate experts and evidence.
However, the same judge — U.S. District Judge Karen Marston, who already presides over the earlier MDL of nearly 3,000 lawsuits alleging that weight-loss drugs caused gastroparesis — will oversee both cases.
The two proceedings will move forward separately, but will coordinate because of overlapping factual issues and defendants.
The newly created MDL centers on claims that Novo Nordisk’s Ozempic, Wegovy and Saxenda, and Eli Lilly’s Trulicity, can trigger non-arteritic anterior ischemic optic neuropathy. The condition is caused by reduced blood flow to the optic nerve, which can result in permanent vision loss or blindness…
READ FULL ARTICLE HERE…
Home | Caravan to Midnight (zutalk.com)
Be First to Comment